Gynecologic Cancers

The NOCC is connecting women who have ovarian cancer to others who are experiencing similar struggles.

In the last two decades, global ovarian cancer mortality rates have either levelled or declined.

Michael Birrer, MD, PhD, Harvard Medical School, discusses what he hopes to discover as factors that influence long-term survival in patients and survivors with ovarian cancer.

A study has found that telephone cancer genetic counseling can be just as effective as in-person counseling for women at risk for hereditary breast and ovarian cancer

While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and interval cytoreduction.

What do patients think about being tested for many genes that may impact their hereditary risk for breast or ovarian cancer, beyond the well-known BRCA mutations?

National guidelines recommend that women with a personal history of ovarian cancer be tested for the BRCA mutation. Approximately 1.3% of women will develop ovarian cancer, according to the National Cancer Institute, but that risk increases to an estimated 39% in women with the BRCA1 mutation and 11% to 17% in women who inherit the BRCA2 mutation.

Michael Birrer, MD, PhD, Harvard Medical School, discusses the importance of personalized care for ovarian cancer.

Researchers at the Dana-Farber Cancer Institute are testing a psychoeducational intervention that they hope will offer relief for sexual problems after treatment.

On May 25, 2016, the American Society of Clinical Oncology (ASCO) released evidence-based, resource-stratified global recommendations on the management and palliative care of women diagnosed with invasive cervical cancer.

Resources and information about possible loss of fertility after cancer treatment and preservation measures to prevent infertility are sorely lacking for young women, according to a new study.

Pregnant and diagnosed with cervical cancer at age 27, I chose treatment and my daughter and I survived what experts said would kill us.

Bright Pink's Women's Health Provider Education program is designed to address gaps in knowledge of young women's genetic cancer risk.

The Julie Fund for Women’s Cancers remains single largest philanthropic source of funding for ovarian cancer research at Massachusetts General Hospital.

This survey is open to any woman diagnosed with ovarian, fallopian tube, or primary peritoneal cancer, regardless of whether or not you have had genetic counseling or testing.

For patients with epithelial ovarian cancer, adjuvant hormone therapy (AHT) proved to be safe and reduced the risk of death by 37%, according to findings of a 24-year study recently published in the Journal of Clinical Oncology.

African American women can reduce their risk of developing ovarian cancer by following healthy dietary guidelines, a recent study has found.

Linked to expansion of health insurance coverage.

Women who develop ovarian cancer are more likely to have better outcomes if they took oral contraceptives prior to their diagnosis, according to a new study by researchers at Mayo Clinic.

Women at an elevated risk of breast cancer may be able to avoid preventive procedures with regular aerobic exercise, according to a new study published in Breast Cancer Research and Treatment.

Genetic counseling before BRCA genetic testing improves patient knowledge, understanding, and satisfaction. However, a new analysis has found that most women undergoing BRCA genetic testing did not receive counseling prior to testing, despite national guidelines and recommendations.

In the past 12 months, women have been more likely to have seen their primary physician, dentist, eye doctor, and hairdresser than their OBGYN, according to results of a new survey.

Sharsheret is a national not-for-profit organization supporting young Jewish women and their families facing breast cancer and ovarian cancer.

Rates of endometrial cancer continue to increase among all racial and ethnic groups, but they're rising faster among non-Hispanic black women who also have poorer outcomes when compared with their white, non-Hispanic counterparts.

Study finds long-term survival is not unusual.

Less than 50% of patients with ovarian cancer who could benefit from intraperitoneal chemotherapy actually receive it, despite research suggesting that this technique could improve survival for these patients.

Oral contraceptives may provide long-term protection against endometrial cancer.

Findings of a new study show that failure to follow professional practice guidelines for weight-based chemotherapy dosing can lead to poorer survival in women with ovarian cancer.